Added back some of what I trimmed. EMBARK looked really good with 3 years of data. Chart is consolidating by the look of it. Currently a 25 ceiling and a 20 floor maybe 18 but 20-25 the past two months looks pretty tight 12/25-1/26 we shall see what happens the rest of 2026. 3 month chart had the mid 20's drop to almost 15 I believe that was because of the ESSENCE (9yr study) with AMONDYS 45 and VYONDYS 53 failed to reach their primary endpoint in Phase III trial. SRPT believes Covid circumstances 'confounded' the data. SRPT wants to meet with the FDA to switch from accelerated to traditional approval. IMO I think this is what's keeping the stock from breaking the 25 ceiling with the positive EMBARK news. Stock is 20.34 closing Friday. If all goes well the 1 year chart shows 35-45 was the next trading range but 25 is always possible with it being the current 'ceiling'. Before that 50 floor with 65 ceiling until Prassad was hired. That was an EPIC crash that SRPT hasn't recovered from. Before any deaths this was over 100 with a high of 175 if going out 1.5 years. 3 year chart SRPT was usually over 100 (before deaths) and had a crash to around 55 (around 11/2023) but went back up over 100 in less than 3 months. So SHORTS are in control now. This is a multiple year play with it probably going back up over 100 but within the above mentioned 'ranges' being where the stock consolidates. Of course GREAT news could just send it higher overnight or tragic news to new lows. The ARWR deal should reward shareholders 5-7 years from now so it really depends on your investing style/desires. Could be a buy and hold for big gains or a flip buy the dips sell the rips which is what I switched to doing while holding a 'core' Flip for freebies I always say...
Market Data 
Markets 
AI
